Invectys will be attending the AACR Annual Meeting 2019. The AACR (American Association for cancer Research) Annual Meeting program covers the latest discoveries…
Après le succès de sa Phase I, Invectys lève 4.3 Millions d’Euros permettant la rentrée en Phase II de ses deux vaccins anticancéreux Paris, le 12…
Presentation of the Invectys clinical trial results on cancer patients at the most important worldwide oncology meeting taking place this year in Chicago, USA Paris,…
Invectys attend ASCO 2017 meeting in Chicago Invectys will be at the Annual Meeting is organized by American Society Of Clinical Oncology (ASCO). This meeting…
Invectys focuses on the development of innovative anti-cancer therapeutic approaches in immunotherapy. It is backed by French and international private investors…
Main achievements Raised over 38 Millions € Moved 2 products into phase II clinical trials 15 patents filed Ongoing 2 phase II clinical trials in the USA and in…
Invectys is a biopharmaceutical company focused on the development of innovative immunotherapy approaches to treat cancers. …
Invectys’ Scientific and Clinical Board is composed of globally recognized top specialists and key opinion leaders: Professor Maurizio Zanetti University…
